This study is a secondary analysis of data from 741 subjects with genetic data in the Clinical Antipsychotics Trials of Intervention Effectiveness (CATIE)-schizophrenia trial. CATIE (2001–2004) was a United States based multisite trial designed to assess differences in antipsychotic efficacy. We refer you to Sullivan et al. (2007) for details on the study design, patient selection criteria, sample details and genotyping. For the CATIE study, a total of 1493 patients with chronic schizophrenia were recruited from several sites to participate in the trial and of these patients, 741 provided a DNA sample. The study excluded first episode patients, treatment resistant patients, patients with mood disorders or features and patients whose symptoms were directly a result of substance use or abuse. Study diagnoses for patients were determined by CATIE investigators using the Structured Clinical Interview for DSM-IV (First, 1995). In addition to the consent for the main trial, patients also provided a separate consent for genetic studies (Sullivan et al., 2007).
